Chernett Amends 13G; Holds 10.23% of Oncology Institute (TOI)

Rhea-AI Filing Summary

Oncology Institute, Inc. amendment to a Schedule 13G reports that Jorey Chernett beneficially owned 10,115,944 shares of Common Stock as of the close of business on March 13, 2026, representing 10.23% of outstanding shares. The filing cites 98,839,144 Shares outstanding as of March 5, 2026 per the company’s Annual Report on Form 10-K filed March 12, 2026. The cover page shows the Reporting Person has sole voting and dispositive power over the 10,115,944 shares. The amendment is signed by Jorey Chernett on March 16, 2026.

Insights

Corporate Governance Analyst

Amendment confirms a >10% stake and sole control over reported shares.

The filing records that Jorey Chernett beneficially owns 10,115,944 shares, equal to 10.23% of the company based on the disclosed 98,839,144 outstanding shares. The cover-page entries list sole voting and dispositive power for the reported shares.

The ownership level surpasses common beneficial-ownership thresholds that can trigger disclosure obligations and may be relevant for governance discussions. Subsequent filings or amendments will show any changes in percentage or voting arrangements.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Oncology Institute, Inc.

(Name of Issuer)

Common Stock, $0.0001 Par Value Per Share

(Title of Class of Securities)

(CUSIP Number)

03/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Chernett Jorey

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 10,115,944.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 10,115,944.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10,115,944.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.2 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Oncology Institute, Inc.
(b)	Address of issuer's principal executive offices: 18000 Studebaker Rd., Ste. 800, CERRITOS, CALIFORNIA, 90703.
Item 2.
(a)	Name of person filing: Jorey Chernett (the "Reporting Person")
(b)	Address or principal business office or, if none, residence: The principal business address of the Reporting Person is 6222 Indianwood Trail, Bloomfield Hills, MI 48301.
(c)	Citizenship: US.
(d)	Title of class of securities: Common Stock, $0.0001 Par Value Per Share
(e)	CUSIP No.:
Item 4.	Ownership
(a)	Amount beneficially owned: As of the close of business on March 13, 2026, the Reporting Person beneficially owned 10,115,944 shares of Common stock, par value $0.0001 per share, of the Issuer (the "Shares").
(b)	Percent of class: The aggregate percentage of Shares owned by the Reporting Person is based upon 98,839,144 Shares outstanding as of March 5, 2026, as disclosed in the Issuer's Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission on March 12, 2026. As of the close of business on March 13, 2026, the Reporting Person may be deemed to beneficially own 10.23% of the outstanding Shares.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Cover Pages Items 5-9.
	(ii) Shared power to vote or to direct the vote: See Cover Pages Items 5-9.
	(iii) Sole power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
	(iv) Shared power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Chernett Jorey

Signature:	/s/ Jorey Chernett
Name/Title:	Jorey Chernett
Date:	03/16/2026

FAQ

What stake did Jorey Chernett report in Oncology Institute (TOI)?

The filing states 10,115,944 shares, representing 10.23% of outstanding Common Stock as of March 13, 2026. The outstanding share base referenced is 98,839,144 as of March 5, 2026 per the issuer's Form 10-K.

Does the filing show voting or dispositive power for the reported shares?

Yes. The cover-page entries list the Reporting Person with sole voting and sole dispositive power over the 10,115,944 shares reported, indicating control to vote and direct disposition of those shares.

What dates anchor the ownership figures in the Schedule 13G/A for TOI?

The beneficial ownership is reported as of the close of business on March 13, 2026, and the outstanding-share count used for the percentage is cited as of March 5, 2026 from the issuer’s Form 10-K filed March 12, 2026.

Was this filing an initial report or an amendment for TOI?

This is labeled Amendment No. 1 to a Schedule 13G, indicating it amends a prior Schedule 13G filing and updates the Reporting Person’s beneficial ownership information and related cover-page disclosures.

Who signed the Schedule 13G/A amendment for Oncology Institute?

The amendment is signed by /s/ Jorey Chernett with the name and title listed as Jorey Chernett, and the signature date shown as March 16, 2026.